Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algita D is an oral nutritional supplement developed and marketed by Labaid Pharmaceuticals in Bangladesh. It is a combination product containing calcium carbonate (500 mg elemental calcium) derived from an algae source and vitamin D3 (200 IU cholecalciferol). The supplement is indicated for the treatment and prevention of bone-related conditions, including osteoporosis, osteomalacia, tetany, hypoparathyroidism, and osteogenesis disorders. Its mechanism of action involves providing essential calcium for bone mineralization and utilizing vitamin D3 to enhance intestinal calcium absorption and maintain systemic calcium homeostasis. The algae-derived calcium source is often highlighted for its potential bioavailability and natural origin compared to mineral-sourced alternatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Algita D.